US · MGNX
MacroGenics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Rockville, MD 20850
- Website
- macrogenics.com
Price · as of 2024-12-31
$3.13
Market cap 125.88M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $34.79 | +1,011.5% |
| Intrinsic Value(DCF) | $0.91 | -70.93% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $1.85 | $15.56 | |||
| 2013 | $33.22 | $47.67 | $4.00 | $3.04 | $0.00 |
| 2014 | $34.77 | $445.05 | $3.68 | $0.00 | $11.12 |
| 2015 | $17.60 | $57.56 | $5,286.57 | $6.69 | $0.00 |
| 2016 | $19.79 | $26.93 | $7.09 | $0.00 | $9.20 |
| 2017 | $30.58 | $83.99 | $4,112.35 | $5.57 | $0.00 |
| 2018 | $19.33 | $411.02 | $1.25 | $0.00 | $211.98 |
| 2019 | $7.42 | $20.49 | $0.68 | $0.00 | $0.00 |
| 2020 | $30.19 | $35.68 | $1.92 | $0.00 | $0.00 |
| 2021 | $8.49 | $21.72 | $0.05 | $0.00 | $45.47 |
| 2022 | $5.32 | $33.40 | $98.12 | $0.00 | $0.00 |
| 2023 | $17.43 | $33.29 | $0.00 | $1.73 | $7.46 |
| 2024 | $2.27 | $34.79 | $1,407.18 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates MacroGenics, Inc.'s (MGNX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $34.79
- Current price
- $3.13
- AI upside
- +1,011.5%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.91
-70.93% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MGNX | MacroGenics, Inc. | $3.13 | 125.88M | +1,012% | -71% | — | — | -2.12 | 1.22 | 0.96 | 0.38 | -0.35 | 1.22 | 91.71% | -74.54% | -45.14% | -49.85% | 242.04% | -23.91% | 0.32 | -99.17 | 3.92 | 3.71 | 2.53 | 61333.00% | 15937.00% | -987.00% | -50.71% | -1.23 | 157.77% | 0.00% | 0.00% | 55.15% | 0.20 | 0.31 | -0.15 | -5.76 |
| CLNN | Clene Inc. | $5.23 | 48.62M | +633% | -65% | — | +3,976% | -0.81 | -3.60 | 93.13 | -1.20 | — | -3.60 | 79.53% | -9676.32% | -11520.47% | -1738.36% | -637.51% | -98.90% | -2.35 | -8.14 | 1.57 | 1.22 | -0.26 | -3987.00% | -4771.00% | -3003.00% | -67.00% | -2.07 | -411.12% | 0.00% | 0.00% | 0.00% | -1.22 | -1.90 | 118.53 | -17.65 |
| CNTB | Connect Biopharma Holding… | $2.47 | 138.08M | — | — | — | — | -3.00 | 0.51 | 1.80 | 2.14 | — | 0.51 | 100.00% | -86.24% | -60.03% | -16.18% | 242.61% | -13.76% | 0.00 | — | 11.46 | 11.20 | 3.58 | -7407.00% | — | -4948.00% | -51.91% | -2.79 | 263.24% | 0.00% | 0.00% | 0.00% | 2.08 | 1.91 | -1.79 | -1.11 |
| CNTX | Context Therapeutics Inc. | $2.25 | 206.73M | — | — | — | — | -1.75 | 0.49 | — | 1.59 | — | 0.49 | 0.00% | — | — | -49.89% | 3929.63% | -46.81% | 0.00 | — | 35.62 | 34.36 | 3.15 | -6933.00% | — | 3927.00% | -62.65% | -5.30 | 3849.40% | 0.00% | 0.00% | 170.46% | 1.58 | 1.62 | — | 8.62 |
| COYA | Coya Therapeutics, Inc. | $4.96 | 82.41M | +515% | -78% | — | +508% | -7.05 | 2.65 | 29.50 | -3.87 | -29.29 | 2.65 | -233.86% | -485.35% | -418.70% | -39.57% | -774.97% | -34.76% | 0.00 | — | 11.59 | 10.22 | 2.23 | 2405.00% | -4079.00% | -804.00% | -9.81% | -2.69 | -484.62% | 0.00% | 0.00% | 5.45% | -3.86 | -6.46 | 18.71 | 11.79 |
| IFRX | InflaRx N.V. | $0.92 | 62.33M | +5,018% | -48% | — | — | -1.32 | 0.99 | 367.43 | -0.95 | — | 0.99 | -1900.76% | -31973.69% | -27784.96% | -56.18% | -78.66% | -46.95% | 0.01 | -2566.39 | 5.06 | 1.30 | 0.39 | 0.00% | 16279.00% | 2826.00% | -79.79% | -3.43 | -72.12% | 0.00% | 0.00% | 9.72% | -0.82 | -0.89 | 261.45 | -5.01 |
| ORMP | Oramed Pharmaceuticals In… | $3.42 | 136.08M | +1,195% | — | — | — | -5.13 | 0.67 | — | 2.94 | — | 0.67 | 0.00% | — | — | -12.29% | -43.99% | -10.14% | 0.00 | -14.98 | 25.19 | 24.97 | 3.63 | -43571.00% | -10000.00% | -2009.00% | -8.62% | -1.48 | -29.02% | 0.00% | 0.00% | 101.31% | 3.42 | 5.19 | — | 5.11 |
| OVID | Ovid Therapeutics Inc. | $1.63 | 116.08M | +1,596% | -87% | — | — | -1.39 | 0.54 | 65.14 | 0.03 | — | 0.54 | 100.00% | -10933.75% | -4670.14% | -33.88% | -444.08% | -22.38% | 0.22 | — | 5.32 | 5.04 | 0.20 | -5000.00% | 4439.00% | 2201.00% | -151.96% | -5.32 | -402.05% | 0.00% | 0.00% | 1.37% | 0.02 | 0.03 | -2.56 | -5.32 |
| STTK | Shattuck Labs, Inc. | $3.92 | 187.78M | +1,035% | -87% | — | — | -0.83 | 0.78 | 10.91 | 0.09 | — | 0.78 | 100.00% | -1408.27% | -1318.13% | -67.23% | -568.84% | -60.18% | 0.04 | — | 8.88 | 8.19 | 0.70 | -2732.00% | 24526.00% | -2580.00% | -97.02% | -6.79 | -427.68% | 0.00% | 0.00% | 0.00% | 0.09 | 0.12 | -1.25 | -4.52 |
| WHWK | Whitehawk Therapeutics In… | $3.51 | 165.42M | +472% | -63% | — | — | -0.90 | 1.09 | 2.21 | -0.17 | — | 1.09 | -108.04% | -259.62% | -245.13% | -80.79% | -3655.27% | -62.83% | 0.02 | -438.04 | 3.59 | 3.11 | 0.43 | -328.00% | 669.00% | -382.00% | -106.81% | -3.49 | -3316.39% | 0.00% | 0.00% | 0.00% | -0.16 | -0.18 | 0.42 | -6.74 |
| ZNTL | Zentalis Pharmaceuticals,… | $2.39 | 172.68M | — | -34% | — | — | -0.78 | 0.38 | 1.92 | 1.07 | — | 0.38 | 100.00% | -283.57% | -245.96% | -42.83% | -4301.81% | -33.43% | 0.13 | — | 7.32 | 7.13 | -0.05 | -4787.00% | — | -1791.00% | -132.25% | -3.24 | -3849.27% | 0.00% | 0.00% | 6.95% | 1.04 | 1.16 | -2.95 | -2.98 |
About MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
- CEO
- Eric Blasius Risser
- Employees
- 341
- Beta
- 1.48
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.91 ÷ $3.13) − 1 = -70.93% (DCF, example).